3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
4
Status
Recruiting
3
Active not recruiting
1
Sponsor Class
INDUSTRY
4
Study Type
Interventional
4
Sponsor
Cancer Type
Gynecologic
4
Conditions
Carcinoma, Non-Small-Cell Lung
17
Prostatic Neoplasms
12
Lung Neoplasms
10
Squamous Cell Carcinoma of Head and Neck
5
Prostatic Neoplasms, Castration-Resistant
4
Parkinson Disease 4, Autosomal Dominant Lewy Body
4
Endometrial Neoplasms
4
Neoplasms
3
Breast Neoplasms
3
Urinary Bladder Neoplasms
2
Stomach Neoplasms
2
Salivary Gland Neoplasms
2
Oropharyngeal Neoplasms
2
Non-Muscle Invasive Bladder Neoplasms
2
Neoplasm Metastasis
2
Nasopharyngeal Carcinoma
2
Lymphoid Interstitial Pneumonia
2
Carcinoma, Transitional Cell
2
Carcinoma
2
Anatomic Stage II Breast Cancer AJCC v8
2
Anatomic Stage I Breast Cancer AJCC v8
2
Uterine Neoplasms
1
Urothelial Cancer
1
Triple Negative Breast Neoplasms
1
Tongue Neoplasms
1
Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v6 and v7
1
Stage I Prostate Adenocarcinoma AJCC v7
1
Solid Tumors
1
Small Cell Lung Carcinoma
1
Selected Subjects With Advanced Solid Tumors
1
Interventions
Paclitaxel
16
pembrolizumab
12
Carboplatin
11
Specimen Handling
10
Magnetic Resonance Spectroscopy
8
Biopsy
7
Taxes
5
Fulvestrant
5
Doxorubicin
5
olaparib
4
dostarlimab
4
Nivolumab
4
Gemcitabine
4
Docetaxel
4
Cisplatin
4
Bevacizumab
4
palbociclib
3
X-Rays
3
Oxaliplatin
3
Leucovorin
3
Fluorouracil
3
trastuzumab deruxtecan
2
ribociclib
2
pertuzumab
2
ipatasertib
2
binimetinib
2
abemaciclib
2
Trastuzumab
2
Surveys and Questionnaires
2
Progestins
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
4 trials
Recent
Start date
Enrollment
Endometrial Neoplasms
×
Docetaxel
×
30 days
×
Clear all
NCT06952504
2026-05-22
TroFuse-033
Merck Sharp & Dohme LLC
Phase 3
Recruiting
1,123 enrolled
NCT06340568
2026-05-20
Fern-EC-01
BioNTech SE
Phase 3
Recruiting
480 enrolled
NCT06989112
2026-05-06
DE-01
AstraZeneca
Phase 3
Recruiting
600 enrolled
NCT05173987
2026-05-05
KEYNOTE-C93
Merck Sharp & Dohme LLC
Phase 3
Active not recruiting
280 enrolled